World Health Organization (WHO) recommends against using remdesivir as a treatment for COVID-19.
Based on data from the WHO SOLIDARITY study which suggests that remdesivir has no important effect on mortality, need for mechanical ventilation, time to clinical improvement and other patient- outcomes, the WHO currently recommends against remdesivir as a COVID-19 treatment.
Source:
Biospace Inc.
SPS commentary:
The WHO guideline development group noted more research is needed, especially to provide higher certainty of evidence for specific groups of patients. They supported continued enrolment in trials evaluating remdesivir.
A BMJ article discusses the role of remdesivir as a treatment for covid-19 in the context of this study and draws parallels to oseltamivir (Tamiflu) which was stockpiled in anticipation of flu pandemics.